For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Join Dr. Hartland Jackson as he provides an overview of epitope-based multiplexed imaging methods and reviews the benefits and challenges of each technique. Hear him discuss his recently-published work using Imaging Mass Cytometry to study the single-cell architecture of biobanked clinical tissue sections, as well as the potential uses of spatially-resolved single-cell methods and analyses.
About the presenters:
Dr. Hartland Jackson
Dr. Hartland Jackson is an Investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health System and is part of the Ontario Institute for Cancer Research. He is also Assistant Professor in the Department of Molecular Genetics at the University of Toronto, Canada. His research involves the use of mass cytometry for highly multiplexed imaging of tumor tissues and the development of methods for the analysis of spatially-resolved single-cell data.
Dr. Jackson obtained his PhD with Dr. Rama Khokha at the University of Toronto and undertook postdoctoral training in Dr. Bernd Bodenmiller’s lab at the University of Zürich. His work with high-dimension pathology imaging of breast cancer patient samples has revealed the organization of the tumor microenvironment and identified single-cell defined patient subgroups with distinct clinical outcomes.
The recently-established Jackson lab strives to understand tissues and tumors as the integrated outcome of their single-cell components. To do so, they utilize multiplexed imaging to simultaneously quantify single-cell phenotypes and markers of their functional state, as well as their interactions, overall organization, and contribution to tissue architecture.
Dr. Subham Basu
Dr. Subham Basu is the Director of Strategy, Immuno-oncology at Abcam. In this role, Subham is responsible for developing and directing the commercial strategy of Abcam’s immuno-oncology portfolio. His vision is to ensure all researchers, in fundamental research, drug discovery, translational medicine and clinical science and across academia, biotech, pharma and diagnostics sectors, can access the best tools and solutions for their immuno-oncology research.
Dr. Basu has extensive experience in pharmaceutical medical affairs and market access. Prior to joining Abcam, Dr. Basu served as an advisor to the pharmaceutical and diagnostic industries as well as to venture capital funds. Having also led a competitive research laboratory at the Cancer Research UK Barts Centre he has hands-on expertise, from preclinical research to the commercial R&D, therapeutic and diagnostic sectors.
Have questions about this webinar? Contact us at firstname.lastname@example.org